Basic Search  |  Summaries  |  Advanced Search

Violation Tracker Individual Record

Company: TAP Pharmaceutical Products Inc.
Current Parent Company: Takeda Pharmaceutical
Penalty: $875,000,000
Year: 2001
Date: October 3, 2001
Offense Group: government-contracting-related offenses
Primary Offense: False Claims Act and related
Secondary Offense: fraud
Mega-Scandal: Improper Drug Marketing
Violation Description: TAP Pharmaceutical agreed to pay a total of $875 million to resolve a case involving fraudulent pricing and improper marketing of its prostate cancer drug Lupron. The amount included a $290 million criminal fine for violating the Prescription Drug Marketing Act; a $559.5 million False Claims Act civil settlement ; and $25.5 million in payments to state governments. TAP was formerly a joint venture of Takeda Pharmaceutical and Abbott Laboratories; the companies dissolved the venture in 2008, and Takeda took over most of its operations.
Level of Government: federal
Action Type: agency action
Agency: Justice Department Civil Division
Civil or Criminal Case: civil and criminal
HQ Country of Current Parent: Japan
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data: (click here)
Source Notes: If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.